Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Endo International (NASDAQ:ENDP), Wright Medical Group (NASDAQ:WMGI) and Dicerna Pharma (NASDAQ:DRNA).
Endo International (ENDP)
Stifel Nicolaus analyst Annabel Samimy reiterated a Hold rating on Endo International yesterday and set a price target of $17. The company’s shares closed yesterday at $16.23, close to its 52-week high of $17.34.
According to TipRanks.com, Samimy is a 4-star analyst with an average return of 10.6% and a 53.1% success rate. Samimy covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, Jazz Pharmaceuticals, and Cara Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Endo International with a $13 average price target, representing a -19.9% downside. In a report issued on August 1, Canaccord Genuity also maintained a Hold rating on the stock with a $13 price target.
.
See today’s analyst top recommended stocks >>
Wright Medical Group (WMGI)
Oppenheimer analyst Steven Lichtman maintained a Hold rating on Wright Medical Group today and set a price target of $28. The company’s shares closed yesterday at $26.30.
Lichtman noted:
“Wright Medical delivered solid 2Q18 sales of $205.4M (+13% constant currency), ahead of our/consensus estimates of $198.7M/$197.2M. The beat was evenly distributed between upper and lower extremities and biologics vs. our model. Management highlighted strength in SIMPLICITI short-stem shoulder supported by uptake of BLUEPRINT enabling technology and faster than expected improvement it saw in core foot/ankle. EBITDA was in line with our estimate. Sales guidance for FY18 was raised by $8M to $808-$820M based on underlying business trends and the recent approval of AUGMENT Injectable; EBITDA was upped by $2M. While Upper Extremities comps toughen in 2H18, WMGI expects further improvement in the launch of PROSTEP minimally invasive, continued improved sales force execution, and contribution of AUGMENT Injectable.”
According to TipRanks.com, Lichtman ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -3.2% and a 52.1% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Motus Gi Holdings Inc.
Currently, the analyst consensus on Wright Medical Group is a Moderate Buy with an average price target of $31.38, which is a 19.3% upside from current levels. In a report released today, Needham also maintained a Hold rating on the stock.
.
Dicerna Pharma (DRNA)
In a report released yesterday, Stephen Willey from Stifel Nicolaus reiterated a Buy rating on Dicerna Pharma, with a price target of $20. The company’s shares closed yesterday at $14.32, close to its 52-week high of $15.80.
According to TipRanks.com, Willey is a 5-star analyst with an average return of 20.8% and a 51.4% success rate. Willey covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Alexion Pharmaceuticals, and Lexicon Pharmaceuticals.
Currently, the analyst consensus on Dicerna Pharma is a Moderate Buy with an average price target of $15.67.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
